Image Source: Pixabay

The 5 constituents in the munKNEE Psychedelic Drug Stocks Index are ranked below in descending order as to their performances this week (as of October 5th), and since the end of August.

1. Atai (ATAI): UP 17.8% this week; DOWN 0.7% since the end of August
   • is focused on the use of ketamine, DMT and ibogaine.  Go here for much more extensive information on Ketamine and here for much more extensive information on DMT.
   • Read:
     • atai Life Sciences Announces Completion of Phase 1 Study of VLS-01 in Healthy Participants
     • atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine)
2. Mind Medicine (MNMD): DOWN 1.6% this week; DOWN 25.3% since the end of August
   • is primarily focused on the use of LSD and MNMA. Go here for much more extensive information on LSD and  here for much more extensive information on MNMA.
   • Read:
     • MindMed Completes Enrollment of Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD)
     • MindMed Reports Second Quarter 2023 Financial Results and Business Highlights
3. Incannex Healthcare (IXHL): DOWN 4.4% this week; DOWN 24.8% since the end of August:
   • is researching and developing therapies and products with the world's largest portfolio of medicinal cannabinoid and psychedelic pharmaceutical products.
   • Read:
     • Incannex to Prepare FDA IND Application for Psilocybin-assisted Psychedelic Psychotherapy Program, Known as Psi-GAD
     • Review of IND Application for IHL-42X by US FDA has been completed; Clinical Trial for Patients with Obstructive Sleep Apnoea May Proceed
4. Compass Pathways (CMPS): DOWN 7.4% this week; DOWN 24.3% since the end of August
   • is focused on the use of psilocybin (magic mushrooms) in their research. Go here for much more extensive information on Psilocybin.
   • Read:
     • COMPASS Pathways announces publication of first study evaluating potential of AI model to predict outcomes of COMP360 psilocybin treatment in treatment-resistant depression
     • COMPASS Pathways Announces Second Quarter 2023 Financial Results and Business Highlights
5. GH Research (GHRS): DOWN 10.3% this week; DOWN 15.1% since the end of August
   • is primarily focused on the use of mebufotenin, the new International non-proprietary name for 5-MeO-DMT, which stands for 5-MethOxy-N,N-DiMeThyltryptamine.
   • Read:
     • GH Research Provides Updates and Guidance on its Clinical Development Program for GH001 in Treatment-Resistant Depression
     • GH Research Reports Second Quarter 2023 Financial Results and Provides Business Updates

Summary 

The revised munKNEE Psychedelic Drug Stocks Index was DOWN 6.3% this week and is now DOWN 19.6% since the end of August.

If you are interested in this category, consider the  AdvisorShares Psychedelic ETF (PSIL) of 23 such stocks, of which the majority have market capitalizations of less than $50M. It was DOWN 5.0% this week and is now DOWN 15.9% since the end of August. 

More By This Author:

Cannabis Stocks: The Decline Continues
AI-Themed "Magnificent Seven" Mega Cap Stocks Up 82% YTD
Tilray's Q1, 2024, Financial Results Leave Investors Unimpressed